Dr. Marc Bonaca and Dr. C Michael Gibson discuss: When is the world ready for Asymptomatic CAD Screening?
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society
Clinical Trial Results
Search
Dr. Danielle Belardo and Dr. C. Michael Gisbon discuss: The Target is the Plaque: Stabilization, Regression, and the Role of Imaging and AI in Modern CAD Management
Sponsored by Cleerly, Women as One and International Atherosclerosis Society
Dr. Masri and Dr. C. Michael Gibson discuss: Effect of Acoramidis on Recurrent and Cumulative Cardiovascular Outcomes in ATTR-CM: Exploratory Analysis from ATTRibute-CM
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.
Dr. Hofmann and Dr. Gibson discuss HELP-MI SWEDEHEART trial
Disclosures: TBD
Dr. Maros Ferencik and Dr. C. Michael Gibson discuss: Clinical Utility of Atherosclerosis Imaging in Symptomatic Patients: Lessons Learned from CCTA
Sponsored by Cleerly, Women as One, and International Atherosclerosis Society
Dr. Kevin Alexander and Dr. C. Michael Gibson discuss: Acoramidis reduces cardiovascular mortality (CVM): results at month 42 from the ATTRibute-CM open-label extension (OLE) study
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.